Using the hiPSC-derived hLORGs, they identified two immunotherapeutic candidates for COVID-19 treatment, a tetravalent neutralizing antibody (15033-7) targeting the spike protein, and a synthetic peptide homologous to the dipeptidyl peptidase-4 (DPP4) receptor on host cells. This evidence concerns the gene DPP4 and COVID-19.